Biotech Deal Toys

Financial tombstone marking a direct common stock offering by Houston, Texas-based Salarius Pharmaceuticals. The proceeds will be used to fund the clinical and preclinical development of cancer drugs. (22AJH070)

Crystal deal toy, incorporating a DNA strand image, celebrating a registered direct offering of stock by Salarius Pharmaceuticals. The Houston-based biopharmaceutical company develops cancer therapies. (22AJH070)

Lucite deal toy recognizing a joint venture between Ironwood Pharmaceuticals and biotechnology firm COUR. The collaboration will allow Ironwood to develop and commercialize COUR's liver disease therapy CNP-104. (22ALJ081)

Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR's therapy for PBC, a rare autoimmune disease affecting the liver. (22ALJ081)

Crystal deal toy marking the ASX debut of Sydney-based biotech Radiopharm Theranostics. (21ALJ553)

Crystal deal toy celebrating the initial public offering on the Australian Securities Exchange (ASX) of Radiopharm Theranostics. The Sydney-based company develops radiopharmaceutical drugs and treatments for cancer. (21ALJ553)

Lucite deal toy, incorporating a spinning logo, celebrating growth capital provided to New York City-based Click Therapeutics. The debt financing will be used for the commercialization of several therapies, including one aimed at smoking cessation. (21AKL594)

Lucite deal toy celebrating the initial public offering (IPO) of Bluejay Diagnostics. The diagnostics and medical device firm is based in Acton, Massachusetts. (21AKL655)

Lucite tombstone commemorating a capital raise by Aditx Therapeutics (Aditxt). The life sciences and biotech firm is based in Richmond, Virginia. (21AKL251)

Custom Lucite celebrating a deal for global rights to the preclinical "gene-silencing" drug ARO-XDH. (21ALJ356)

Lucite deal tombstone commemorating an agreement for global rights to gout treatment drug ARO-XDH. The agreement was reached between Dublin, Ireland-based Horizon Therapeutics and Arrowhead Pharmaceuticals, headquartered in Pasadena, California. (21ALJ356)

Side view of deal tombstone celebrating Series B financing for Texas-based OncoNano Medincine. The funds will be applied to clinical trials of an imaging agent aimed at improving detection of cancerous tissue. (21ALJ040)

Glow-in-the-dark deal Lucite deal toy commemorating Series B financing for OncoNano Medicine. The funds will be put toward clinical trials for pegsitaciaianine, a fluorescent imaging agent. (21ALJ040)

Lucite tombstone celebrating Series B financing for Texas-based biotech firm OncoNano Medicine. (21ALJ040)

Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer. (21ADH006)

Custom Lucite commemorating a development and commercialization agreement between Japanese drug maker Takeda and California-based Arrowhead Pharmaceuticals. The agreement centers on drugs that treat disease by using RNA to block gene expression. (21ALJ357)

Lucite commemorative celebrating a development and commercialization agreement between Takeda and Arrowhead Pharmaceuticals. (21ALJ357)

Back view of crystal tombstone commemorating a senior bond offering by Siegfried Holding. Based in Switzerland, the life sciences company provides both primary and secondary drug manufacturing. (21LSS233)

Financial tombstone marking the successful placement by Siegfried Holding of a senior bond. The Swiss firm provides development and production services to the pharmaceutical and life sciences sectors. (21LSS233)

Back view of custom financial tombstone recognizing a public offering by electroCore. The commercial-stage bioelectric medicine firm is based in Basking Ridge, New Jersey. (21AJH117)

Side view of deal tombstone marking a follow-0n offering by New Jersey-based electroCore. (21AJH117)

Crystal deal toy commemorating a follow-on offering by electroCore, a bioelectronic medicine company. (21AJH117)

Financial tombstone marking a private placement by X4 Pharmaceuticals. (21ALJ247)

Crystal deal toy commemorating a private placement by X4 Pharmaceuticals. (21ALJ247)

Crystal deal tombstone celebrating Series A financing for Interius BioTherapeutics. The gene therapy developer is based in Philadelphia. (21AKL266)

Crystal deal toy commemorating Series A financing for Interius BioTherapeutics,  a preclinical stage gene therapy firm. (21AKL266)

Back view of custom crystal celebrating the initial public offering on the Australia Securities Exchange of Chimeric Therapeutics. (21ALJ210)

Crystal commemorative marking the initial public offering of Australian biotech firm Chimeric Therapeutics. The firm is developing a class of cell therapy drugs for the treatment of cancer. (21ALJ210)

Lucite deal toy marking crossover funding provided to biotech firm AbSci. (21ALJ163)

Lucite tombstone commemorating crossover funding for AbSci, a Vancouver, Washington-based biotech firm. (21ALJ163)